Reflection on today's RNS . . .21 Sep 2017 20:37
I am of the opinion that today's announcement by the BOD of AMYT is in actual fact a very positive one which, provides an extremely sound and secure fiscal platform and catalyst from which the BOD/company is now able to accelerate the attainment of its stated aims and objectives i.e. the proceeds of the 'placing' will be used to fund the following;
− the Company's ongoing pivotal Phase III clinical trial for AP101, a potential treatment for Epidermolysis Bullosa ("EB"), a rare, genetic skin disorder.
− the pre-launch costs of AP101, in anticipation of a successful Phase III trial.
− an increase in existing manufacturing capacity for the production of AP101.
− the further commercialisation of Lojuxta, the Company's existing revenue generating drug treatment for Homozygous Familial Hypercholesterolemia ("HoFH"), a rare and life-threatening cholesterol disorder.
− the further development of AP102, Amryt's early stage asset that targets resistant acromegaly and Cushing's Disease.
− working capital and future research and development activities.
In light of the above and after having undertaken an evaluative economics scoping analysis in respect of the upside potential of the future target markets, along with the associated and accompanying potential revenue generating capacity of the above, I personally see significant upside potential here and whilst today's announcement clearly frustrates many on this BB, I would respectfully urge you to both reflect on that which the BOD have achieved to date, along with a mid to longer-term perspective as to what the BOD of AMYT are endeavouring to achieve.
Sign In
Follow the stocks
